JG
VERV

Jefferies Group’s Verve Therapeutics VERV Stock Holding History

Jefferies Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$431K Buy
+12,545
New +$400K ﹤0.01% 1084

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Jefferies Group's VERV Position: Q3 2022 in Review

Jefferies Group opened a new position in Verve Therapeutics (VERV) in Q3 2022: 12,545 shares worth $431K. The stake represents ﹤0.01% of the portfolio and ranks #1084 among its holdings.

125 funds tracked by Wall St. Rank hold VERV as of Q3 2022.

  • Jefferies Group held 12,545 shares of Verve Therapeutics worth $431K as of Q3 2022.
  • Verve Therapeutics was a new Jefferies Group position in Q3 2022.
  • Verve Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1084 holding.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.